Andrew C Harris1, Laura Tally2, Peter Muelken3, Andrew Banal4, Clare E Schmidt5, Qing Cao6, Mark G LeSage7. 1. Minneapolis Medical Research Foundation, Minneapolis, MN, United States; Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, United States; Department of Psychology, University of Minnesota, Minneapolis, MN, United States. Electronic address: harr0547@umn.edu. 2. Minneapolis Medical Research Foundation, Minneapolis, MN, United States. 3. Minneapolis Medical Research Foundation, Minneapolis, MN, United States; Department of Ecology, Evolution, and Behavior, University of Minnesota, Minneapolis, MN, United States. 4. Minneapolis Medical Research Foundation, Minneapolis, MN, United States; Department of Psychology, University of Minnesota, Minneapolis, MN, United States. 5. Minneapolis Medical Research Foundation, Minneapolis, MN, United States; Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States. 6. Masonic Cancer Center Biostatistics and Bioinformatics Core, University of Minnesota, Minneapolis, MN, United States. 7. Minneapolis Medical Research Foundation, Minneapolis, MN, United States; Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, United States; Department of Psychology, University of Minnesota, Minneapolis, MN, United States.
Abstract
BACKGROUND: While nicotine is the primary addictive compound in tobacco, other tobacco constituents including minor alkaloids (e.g., nornicotine, anabasine) may also contribute to tobacco addiction by mimicking or enhancing the effects of nicotine. Further evaluating the behavioral effects of minor alkaloids is essential for understanding their impact on tobacco addiction and informing development of tobacco product standards by the FDA. METHODS: This study compared the addiction-related effects of nicotine and the minor alkaloids nornicotine, anabasine, myosmine, anatabine, and cotinine on intracranial self-stimulation (ICSS) thresholds in rats. RESULTS: Acute injection of nicotine produced reinforcement-enhancing (ICSS threshold-decreasing) effects at low to moderate doses, and reinforcement-attenuating/aversive (ICSS threshold-increasing) effects at high doses. Nornicotine and anabasine produced similar biphasic effects on ICSS thresholds, although with lower potency compared to nicotine. Myosmine only elevated ICSS thresholds at relatively high doses, while anatabine and cotinine did not influence ICSS thresholds at any dose. None of the alkaloids significantly influenced ICSS response latencies, indicating a lack of nonspecific motoric effects. CONCLUSIONS: These findings indicate that some minor tobacco alkaloids can either fully (nornicotine, anabasine) or partially (myosmine) mimic nicotine's addiction-related effects on ICSS, albeit at reduced potency. These findings emphasize the need for further study of the abuse potential of minor alkaloids, including evaluation of their effects when combined with nicotine and other tobacco constituents to better simulate tobacco exposure in humans. Such work is essential for informing FDA regulation of tobacco products and could also lead to the development of novel pharmacotherapies for tobacco addiction.
BACKGROUND: While nicotine is the primary addictive compound in tobacco, other tobacco constituents including minor alkaloids (e.g., nornicotine, anabasine) may also contribute to tobacco addiction by mimicking or enhancing the effects of nicotine. Further evaluating the behavioral effects of minor alkaloids is essential for understanding their impact on tobacco addiction and informing development of tobacco product standards by the FDA. METHODS: This study compared the addiction-related effects of nicotine and the minor alkaloidsnornicotine, anabasine, myosmine, anatabine, and cotinine on intracranial self-stimulation (ICSS) thresholds in rats. RESULTS: Acute injection of nicotine produced reinforcement-enhancing (ICSS threshold-decreasing) effects at low to moderate doses, and reinforcement-attenuating/aversive (ICSS threshold-increasing) effects at high doses. Nornicotine and anabasine produced similar biphasic effects on ICSS thresholds, although with lower potency compared to nicotine. Myosmine only elevated ICSS thresholds at relatively high doses, while anatabine and cotinine did not influence ICSS thresholds at any dose. None of the alkaloids significantly influenced ICSS response latencies, indicating a lack of nonspecific motoric effects. CONCLUSIONS: These findings indicate that some minor tobaccoalkaloids can either fully (nornicotine, anabasine) or partially (myosmine) mimic nicotine's addiction-related effects on ICSS, albeit at reduced potency. These findings emphasize the need for further study of the abuse potential of minor alkaloids, including evaluation of their effects when combined with nicotine and other tobacco constituents to better simulate tobacco exposure in humans. Such work is essential for informing FDA regulation of tobacco products and could also lead to the development of novel pharmacotherapies for tobacco addiction.
Authors: Brandon J Hall; Corinne Wells; Cheyenne Allenby; Mung Yan Lin; Ian Hao; Lindsey Marshall; Jed E Rose; Edward D Levin Journal: Pharmacol Biochem Behav Date: 2014-02-21 Impact factor: 3.533
Authors: Andrew C Harris; Laura Tally; Clare E Schmidt; Peter Muelken; Irina Stepanov; Subhrakanti Saha; Rachel Isaksson Vogel; Mark G LeSage Journal: Drug Alcohol Depend Date: 2014-12-23 Impact factor: 4.492
Authors: Andrew C Harris; Christina Mattson; Mark G Lesage; Daniel E Keyler; Paul R Pentel Journal: Pharmacol Biochem Behav Date: 2010-05-18 Impact factor: 3.533
Authors: Krista Spiller; Zheng-Xiong Xi; Xia Li; Charles R Ashby; Patrick M Callahan; Ashok Tehim; Eliot L Gardner Journal: Neuropharmacology Date: 2009-04-22 Impact factor: 5.250
Authors: Julie A Marusich; Mahesh Darna; A George Wilson; Emily D Denehy; Amanda Ebben; Agripina G Deaciuc; Linda P Dwoskin; Michael T Bardo; Timothy W Lefever; Jenny L Wiley; Chad J Reissig; Kia J Jackson Journal: Eur J Pharmacol Date: 2017-08-26 Impact factor: 4.432
Authors: Yayi Swain; Peter Muelken; Annika Skansberg; Danielle Lanzdorf; Zachary Haave; Mark G LeSage; Jonathan C Gewirtz; Andrew C Harris Journal: Psychopharmacology (Berl) Date: 2020-05-09 Impact factor: 4.530
Authors: Andrew C Harris; Peter Muelken; Yayi Swain; Mary Palumbo; Vipin Jain; Maciej L Goniewicz; Irina Stepanov; Mark G LeSage Journal: Drug Alcohol Depend Date: 2019-08-01 Impact factor: 4.492
Authors: Christie D Fowler; Cassandra D Gipson; Bethea A Kleykamp; Laura E Rupprecht; Paul T Harrell; Vaughan W Rees; Thomas J Gould; Jason Oliver; Deniz Bagdas; M Imad Damaj; Heath D Schmidt; Alexander Duncan; Mariella De Biasi Journal: Nicotine Tob Res Date: 2018-06-07 Impact factor: 4.244
Authors: M G LeSage; M Staley; P Muelken; J R Smethells; I Stepanov; R I Vogel; P R Pentel; A C Harris Journal: Drug Alcohol Depend Date: 2016-09-01 Impact factor: 4.492